- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
ALKEM
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Alkem Laboratories Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
5,620 INR
-2.1%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is 2.4% above the Trend Line and sits at 77.6% of its 52-week range. The latest completed week returned -2.1%, after a -0.7% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 44/100. Near-term considerations: volume confirmation is below normal.
Setup score
52
out of 100
Latest Close
5,620 INR
7 Aug 2026
1W Return
-2.1%
latest completed week
4W Return
-0.7%
short-term follow-through
12W Return
2.4%
quarterly tape
Trend Breadth
55.8%
29 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Latest weekly return ranks in the weaker part of its sector group.
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-2.1%
Latest completed week; four-week move -0.7%.
Indicator stack
31/79
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
44/100
18 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 2.4% above the Trend Line and sits at 77.6% of its 52-week range. The latest completed week returned -2.1%, after a -0.7% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2912-week average 0.18
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.29Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -0.7% over four weeks, 2.4% over 12 weeks, and 18.9% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year29
Trend breadth55.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.99Latest activity-pressure read.
Pressure change143.3%Four-week change in activity pressure.
Leadership3.00Latest relative-leadership reading.
RS change-54.3%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 94%
Model confidence 88%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength67/100Blend of value, momentum, and quality. Underlying universe rank 34; rank 1 is best.
Value31/100Relative valuation strength. Underlying universe rank 70; rank 1 is best.
Quality85/100Profitability and accounting quality. Underlying universe rank 16; rank 1 is best.
Momentum79/100Medium-term price momentum. Underlying universe rank 22; rank 1 is best.
Growth40/100Revenue and earnings growth. Underlying universe rank 61; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework52/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 29.2x Price divided by trailing earnings.
- Price / sales
- 4.6x Market value relative to trailing revenue.
- EV / EBITDA
- 20.4x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 1.9% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 65.4% Gross profit retained from each unit of revenue.
- Operating margin
- 17.8% Operating profit retained from revenue.
- Free-cash-flow margin
- 9.1% Free cash flow generated from revenue.
- Return on invested capital
- 12.6% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 13.5% Latest one-year revenue growth.
- EPS growth
- 6.3% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 8.8% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.9% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.9% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.5x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment44/100
Weighted news tone is neutral across 18 relevant articles.
2 positive · 13 neutral · 3 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-4.5%Distance below the 52-week high.
13-week volatility2.1%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher15 of 2611 weeks finished lower.
Best week+4.6%Week of 27 Feb.
Worst week-6.2%Week of 24 Apr.
Latest week-2.1%Week of 7 Aug.
Shape of recent returns
Strong gains1
Modest gains14
Flat weeks0
Modest losses8
Sharp losses3
Recent vol2.1%13-week weekly-return volatility.
Base vol2.8%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew2.2% / -1.9%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank57 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank46 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape51/100
Trend, activity pressure, participation, and risk combine to a 51/100 tape read.
Indicator analysis43/100Latest 12-week confirmation: trend 0/12, activity pressure 6/12, relative leadership 12/12.
Activity pressure 0.29; No reversal markers Factors65/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 23 SVQF52/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 764.5 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment44/100Weighted news tone is neutral across 18 relevant articles.
Alkem Laboratories Shares Decline Over 2% in Today's Session Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 5,620 INR | -2.1% | 5,488 INR | 5,110 INR | 0.99 | 3.00 | 434.6K | Off |
| 31 Jul 2026 | 5,740 INR | 2.1% | 5,492 INR | 5,097 INR | 1.04 | 6.32 | 628.6K | Off |
| 24 Jul 2026 | 5,623 INR | 1.3% | 5,486 INR | 5,086 INR | 0.85 | 7.22 | 352.5K | Off |
| 17 Jul 2026 | 5,553 INR | -1.9% | 5,481 INR | 5,075 INR | 0.70 | 3.75 | 1.1M | Off |
| 10 Jul 2026 | 5,659 INR | 1.9% | 5,480 INR | 5,063 INR | 0.41 | 6.57 | 544.6K | Off |
| 3 Jul 2026 | 5,553 INR | 2.4% | 5,477 INR | 5,048 INR | -0.02 | 4.69 | 568.3K | Off |
| 26 Jun 2026 | 5,425 INR | 1.0% | 5,480 INR | 5,034 INR | -0.40 | 3.55 | 0 | Off |
| 19 Jun 2026 | 5,374 INR | 1.4% | 5,487 INR | 5,022 INR | -0.22 | 3.08 | 82.9K | Off |
| 12 Jun 2026 | 5,298 INR | 0.9% | 5,496 INR | 5,008 INR | -0.20 | 3.63 | 67.3K | Off |
| 5 Jun 2026 | 5,252 INR | -4.5% | 5,509 INR | 4,995 INR | -0.12 | 4.13 | 143.8K | Off |
| 29 May 2026 | 5,498 INR | 1.7% | 5,521 INR | 4,983 INR | 0.04 | 8.49 | 1.7M | Off |
| 22 May 2026 | 5,404 INR | -1.5% | 5,520 INR | 4,969 INR | -0.31 | 6.15 | 443.9K | Off |
| 15 May 2026 | 5,486 INR | -1.8% | 5,524 INR | 4,955 INR | -0.51 | 8.27 | 271.1K | Off |
| 8 May 2026 | 5,586 INR | 3.4% | 5,525 INR | 4,940 INR | -0.53 | 8.05 | 437.1K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.